These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33328328)

  • 1. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease.
    Rodrigues FB; Byrne LM; Tortelli R; Johnson EB; Wijeratne PA; Arridge M; De Vita E; Ghazaleh N; Houghton R; Furby H; Alexander DC; Tabrizi SJ; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Transl Med; 2020 Dec; 12(574):. PubMed ID: 33328328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
    Caron NS; Byrne LM; Lemarié FL; Bone JN; Aly AE; Ko S; Anderson C; Casal LL; Hill AM; Hawellek DJ; McColgan P; Wild EJ; Leavitt BR; Hayden MR
    Transl Neurodegener; 2024 Oct; 13(1):50. PubMed ID: 39380076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
    Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
    Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
    Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
    Wild EJ; Boggio R; Langbehn D; Robertson N; Haider S; Miller JR; Zetterberg H; Leavitt BR; Kuhn R; Tabrizi SJ; Macdonald D; Weiss A
    J Clin Invest; 2015 May; 125(5):1979-86. PubMed ID: 25844897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament light protein in blood predicts regional atrophy in Huntington disease.
    Johnson EB; Byrne LM; Gregory S; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RA; Zetterberg H; Tabrizi SJ; Scahill RI; Wild EJ;
    Neurology; 2018 Feb; 90(8):e717-e723. PubMed ID: 29367444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.
    Caron NS; Banos R; Aly AE; Xie Y; Ko S; Potluri N; Anderson C; Black HF; Anderson LM; Gordon B; Southwell AL; Hayden MR
    Neurobiol Dis; 2022 May; 166():105652. PubMed ID: 35143966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
    Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
    J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.
    Fodale V; Boggio R; Daldin M; Cariulo C; Spiezia MC; Byrne LM; Leavitt BR; Wild EJ; Macdonald D; Weiss A; Bresciani A
    J Huntingtons Dis; 2017; 6(4):349-361. PubMed ID: 29125493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease.
    Morena E; Romano C; Marconi M; Diamant S; Buscarinu MC; Bellucci G; Romano S; Scarabino D; Salvetti M; Ristori G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model.
    Marchionini DM; Liu JP; Ambesi-Impiombato A; Kerker K; Cirillo K; Bansal M; Mushlin R; Brunner D; Ramboz S; Kwan M; Kuhlbrodt K; Tillack K; Peters F; Rauhala L; Obenauer J; Greene JR; Hartl C; Khetarpal V; Lager B; Rosinski J; Aaronson J; Alam M; Signer E; Muñoz-Sanjuán I; Howland D; Zeitlin SO
    JCI Insight; 2022 Oct; 7(20):. PubMed ID: 36278490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-related Huntingtin seeding activities in cerebrospinal fluids of Huntington's disease patients.
    Lee CYD; Wang N; Shen K; Stricos M; Langfelder P; Cheon KH; Cortés EP; Vinters HV; Vonsattel JP; Wexler NS; Damoiseaux R; Frydman J; Yang XW
    Sci Rep; 2020 Nov; 10(1):20295. PubMed ID: 33219289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nemo-like kinase reduces mutant huntingtin levels and mitigates Huntington's disease.
    Jiang M; Zhang X; Liu H; LeBron J; Alexandris A; Peng Q; Gu H; Yang F; Li Y; Wang R; Hou Z; Arbez N; Ren Q; Dong JL; Whela E; Wang R; Ratovitski T; Troncoso JC; Mori S; Ross CA; Lim J; Duan W
    Hum Mol Genet; 2020 May; 29(8):1340-1352. PubMed ID: 32242231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between prognostic index scores and plasma neurofilament light in Huntington's disease.
    Parkin GM; Corey-Bloom J; Long JD; Snell C; Smith H; Thomas EA
    Parkinsonism Relat Disord; 2022 Apr; 97():25-28. PubMed ID: 35276585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?
    Niemelä V; Landtblom AM; Blennow K; Sundblom J
    PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.
    Scahill RI; Zeun P; Osborne-Crowley K; Johnson EB; Gregory S; Parker C; Lowe J; Nair A; O'Callaghan C; Langley C; Papoutsi M; McColgan P; Estevez-Fraga C; Fayer K; Wellington H; Rodrigues FB; Byrne LM; Heselgrave A; Hyare H; Sampaio C; Zetterberg H; Zhang H; Wild EJ; Rees G; Robbins TW; Sahakian BJ; Langbehn D; Tabrizi SJ
    Lancet Neurol; 2020 Jun; 19(6):502-512. PubMed ID: 32470422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin.
    Tan Z; Dai W; van Erp TG; Overman J; Demuro A; Digman MA; Hatami A; Albay R; Sontag EM; Potkin KT; Ling S; Macciardi F; Bunney WE; Long JD; Paulsen JS; Ringman JM; Parker I; Glabe C; Thompson LM; Chiu W; Potkin SG
    Mol Psychiatry; 2015 Nov; 20(11):1286-93. PubMed ID: 26100538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children.
    Byrne LM; Schultz JL; Rodrigues FB; van der Plas E; Langbehn D; Nopoulos PC; Wild EJ
    Mov Disord; 2022 Jul; 37(7):1526-1531. PubMed ID: 35437792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between lifestyle and serum neurofilament light protein in Huntington's disease.
    Cruickshank T; Bartlett D; Govus A; Hannan A; Teo WP; Mason S; Lo J; Ziman M
    Brain Behav; 2020 May; 10(5):e01578. PubMed ID: 32181593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.